MedTrace Logo

Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging

NCT01522378 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2017-04-26

No results posted yet for this study

Summary

Subjects were recruited if their healthcare provider decided that they needed treatment with a special Internal Cardiac Defibrillator (ICD) called a biventricular ICD. The investigators did this study to see if part of the nerve organ, called the sympathetic nervous system, may be responsible for the improvement seen in patients that receive biventricular pacing. The investigators had three ways to measure sympathetic nervous activity: 1) by using a special blood sample, 2) by monitoring heart rhythm, and 3) by performing a special heart scan.

Conditions

  • Congestive Heart Failure

Interventions

DRUG

123 iodine metaiodobenzylguanidine

10 millicurie (mCi) (370 MBq)

Sponsors & Collaborators

  • GE Healthcare

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Yongmei Cha, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2016-02-29
Completion
2016-02-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01522378 on ClinicalTrials.gov